Lv12
60 积分 2024-04-30 加入
Metabolic syndrome
19天前
已完结
Continued treatment with secukinumab is associated with high retention or regain of response
20天前
已完结
Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study
21天前
已完结
Early inadequate response to biological agents portends treatment failure at 6 months in patients with psoriasis: A multicenter, prospective cohort study
21天前
已完结
Antibiotic Use and the Persistence of Biologic Therapies in Patients With Psoriasis
21天前
已完结
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
25天前
已完结
A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis
27天前
已完结
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study
28天前
已完结
Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years
28天前
已完结
Higher body weight in Chinese patients is associated with treatment resistance to fixed-dose interleukin-17 inhibition with ixekizumab but not to weight-adjusted secukinumab therapy
28天前
已完结
皖公网安备34019202002308
